Pancreatic Cancer Research

ResearcherManchester Academic Health Science CentreActive in the last 2 years

Mairead Geraldine McNamara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2272-3678; OpenAlex author ID A5041768679. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 4 papers · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 26

  1. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  2. Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions. Co-author DOI 10.3390/curroncol31090385↗
  3. Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers15030738↗
  4. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy … Co-author DOI 10.3390/cancers15082277↗
  5. Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre. Last author DOI 10.3390/healthcare11202802↗
  6. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2022.02.014↗
  7. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemothera… Co-author DOI 10.1080/0284186x.2022.2053198↗
  8. The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.21037/hbsn-22-380↗
  9. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Co-author DOI 10.1038/s41467-021-27607-8↗
  10. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy … Co-author DOI 10.1136/bmjopen-2020-042067↗
  11. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. Last author DOI 10.3390/cancers13153779↗
  12. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. First author DOI 10.1002/cam4.3269↗
  13. The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. Co-author DOI 10.1016/j.pan.2020.03.020↗
  14. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.09.012↗
  15. The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001486↗
  16. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Last author DOI 10.1002/jso.25440↗
  17. Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It c… Co-author DOI 10.1002/jso.25691↗
  18. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Co-author DOI 10.1038/s41598-019-47489-7↗
  19. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. Co-author DOI 10.4251/wjgo.v11.i2.102↗
  20. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.currproblcancer.2018.01.013↗
  21. Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? Last author DOI 10.1016/j.ejso.2018.07.047↗
  22. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Last author DOI 10.3390/cancers10010017↗
  23. Germline mutations in pancreatic cancer and potential new therapeutic options. Last author DOI 10.18632/oncotarget.17291↗
  24. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.3390/ijms18050909↗
  25. 18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2015.12.014↗
  26. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? Last author DOI 10.3748/wjg.v22.i32.7175↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan W. Valle · 21 shared papers, 2016–2023 · strength 2.71
  2. Richard A Hubner · 15 shared papers, 2016–2024 · strength 2.03
  3. Ángela Lamarca · 15 shared papers, 2016–2023 · strength 1.90
  4. Rille Pihlak · 8 shared papers, 2017–2023 · strength 0.94
  5. Lindsay E. Carnie · 4 shared papers, 2020–2023 · strength 0.55
  6. Derek A O'Reilly · 4 shared papers, 2018–2020 · strength 0.42
  7. Eitan Amir · 3 shared papers, 2017–2019 · strength 0.39
  8. Nicola de Liguori Carino · 3 shared papers, 2018–2022 · strength 0.37
  9. Ganesh Radhakrishna · 2 shared papers, 2018–2022 · strength 0.26
  10. Roseanna C. Wheatley · 1 shared paper, 2022 · strength 0.26
  11. Daniel Netto · 1 shared paper, 2024 · strength 0.26
  12. Alexandra R. Lewis · 2 shared papers, 2016–2018 · strength 0.23
  13. Ajith Kumar Siriwardena · 2 shared papers, 2018–2020 · strength 0.19
  14. David J. Propper · 1 shared paper, 2025 · strength 0.19
  15. Christine Hughes · 1 shared paper, 2025 · strength 0.19
  16. Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.19
  17. Debashis Sarker · 1 shared paper, 2025 · strength 0.19
  18. Claude Chelala · 1 shared paper, 2025 · strength 0.19
  19. Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.19
  20. David Kuang-Fu Chang · 1 shared paper, 2025 · strength 0.19
  21. Hemant Mahendrakumar Kocher · 1 shared paper, 2025 · strength 0.19
  22. Pippa G. Corrie · 1 shared paper, 2025 · strength 0.19
  23. Simon Gray · 1 shared paper, 2022 · strength 0.17
  24. Rozana Abdul Rahman · 1 shared paper, 2021 · strength 0.17
  25. Sarah Clelland · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.